ArticleMolecular cancer therapeutics2023

Discovery and Preclinical Characterization of XMT-1660, an Optimized B7-H4-Targeted Antibody-Drug Conjugate for the Treatment of Cancer.

Dorin Toader et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.